Chronic obstructive pulmonary disease: Risk and benefit of testosterone therapy;Bronchopneumopathie chronique obstructive: Risques et béné fices d'un traitement de testostérone

Revue Medicale Suisse

Volumn 8, Issue 363, 2012, Pages 2224-2227

  Samaras, N ^a   Samaras, D ^b   Lang, P O ^d,e   Bridevaux, P O ^c   Gex, G ^c   Janssens, J P ^c   Pichard, C ^b  

^a HUG   (Switzerland)

^b HUG   (Switzerland)

^c HUG   (Switzerland)

^d CRANFIELD UNIVERSITY   (United Kingdom)

^e CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; EXERCISE TOLERANCE; HUMAN; HYPOGONADISM; MORBIDITY; MORTALITY; MUSCLE MASS; MUSCLE STRENGTH; PULMONARY REHABILITATION; REVIEW; TREATMENT DURATION;

ANDROGENS; EXERCISE TOLERANCE; HUMANS; MUSCULAR ATROPHY; PHYSICAL ENDURANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TESTOSTERONE;

EID: 84871910503     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Samaras N, Frangos E, Forster A, et al. Andropause : A review of the definition and treatment. Eur Geriatr Med ; epub ahead of print.
2. Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev 1985;6:151-82.
3. Engelen MP, Schols AM, Baken WC, et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994;7:1793-7. (Pubitemid 24337350)
4. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-6. (Pubitemid 23149871)
5. Lewis MI, Fournier M, Storer TW, et al. Skeletal muscle adaptations to testosterone and resistance training in men with COPD. J Appl Physiol 2007;103:1299-310. (Pubitemid 47605967)
6. Maltais F, Simard AA, Simard C, et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996;153:288-93. (Pubitemid 26026864)
7. Jobin J, Maltais F, Doyon JF, et al. Chronic obstructive pulmonary disease : Capillarity and fiber-type characteristics of skeletal muscle. J Cardiopulm Rehabil 1998;18:432-7. (Pubitemid 29024891)
8. **Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001;164:1712-7. (Pubitemid 33124163)
9. Laghi F, Antonescu-Turcu A, Collins E, et al. Hypogonadism in men with chronic obstructive pulmonary disease : Prevalence and quality of life. Am J Respir Crit Care Med 2005;171:728-33. (Pubitemid 40471143)
10. Svartberg J, Schirmer H, Medbo A, et al. Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromso study. Eur J Epidemiol 2007;22:107-12. (Pubitemid 46457302)
11. van der Poll T, Romijn JA, Endert E, et al. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism 1993;42:303-7. (Pubitemid 23073346)
12. *Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:870-8. (Pubitemid 39346482)
13. *Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men : A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639-50.
14. Schols AM, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995;152:1268-74.
15. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998;114:19-28. (Pubitemid 28337356)
16. Yeh SS, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 2002;122:421-8. (Pubitemid 35002116)
17. Svartberg J, Aasebo U, Hjalmarsen A, et al. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004;98:906-13. (Pubitemid 39069342)
18. **Pison CM, Cano NJ, Cherion C, et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure : A randomised controlled trial. Thorax 2011;66:953-60.
19. **Bhasin S, Basaria S. Diagnosis and treatment of hypogonadism in men. Best Pract Res Clin Endocrinol Metab 2011;25:251-70.
20. Pierorazio PM, Ferrucci L, Kettermann A, et al. Serum testosterone is associated with aggressive prostate cancer in older men : Results from the Baltimore longitudinal study of aging. BJU Int 2010;105:824-9.
21. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer : A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83. (Pubitemid 351480553)
22. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.